Avoid common mistakes on your manuscript.
American Journal of Clinical Dermatology (2024) 25:299–314 https://doi.org/10.1007/s40257-024-00846-3
A video abstract is now available for this publication, which can be viewed online. The video abstract can also be accessed on the article’s Figshare page here: https://doi.org/10.6084/m9.figshare.24749436 and in the parent article as Supplementary file 3.
Video abstract: Integrated safety analysis of ritlecitinib in patients aged ≥ 12 years with alopecia areata (MP4 1.03 gb)
Video abstract: Integrated safety analysis of ritlecitinib in patients aged ≥ 12 years with alopecia areata (MP4 1.03 gb).
In Supplementary file2, Table S11, “Lymphocytes, n/N1 (%)c, Grade 3 (200 to < 500/mm3)” row, “Any ritlecitinib (n=1294)” column, the data that previously read:
“27/128 (2.1)”
should have read:
“27/1286 (2.1)”
The original Supplementary file 2 has been corrected.
Author information
Authors and Affiliations
Corresponding author
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
About this article
Cite this article
King, B., Soung, J., Tziotzios, C. et al. Correction to: Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program. Am J Clin Dermatol 25, 689 (2024). https://doi.org/10.1007/s40257-024-00864-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40257-024-00864-1